Heparin and Warfarin Anticoagulation Intensity As Predictors of Recurrence After Deep Vein Thrombosis or Pulmonary Embolism: a Population-based Cohort Study

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2011 Sep 6

PMID 21890644

Citations 32

Authors

John A Heit

Brian D Lahr

Tanya M Petterson

Kent R Bailey

Aneel A Ashrani

L Joseph Melton 3rd

Affiliations

Soon will be listed here.

Abstract

To test recommended anticoagulation measures as predictors of 180-day venous thromboembolism (VTE) recurrence, we identified all Olmsted County, MN residents with incident VTE over the 14-year period of 1984-1997, and followed each case (N = 1166) forward in time for VTE recurrence. We tested the activated partial thromboplastin time (APTT), international normalized ratio (INR), and other measures of heparin and warfarin anticoagulation as predictors of VTE recurrence while controlling for baseline and time-dependent characteristics using Cox proportional hazards modeling. Overall, 1026 (88%) and 989 (85%) patients received heparin and warfarin, respectively, and 85 (8%) developed VTE recurrence. In multivariable analyses, increasing proportions of time on heparin with an APTT ≥ 0.2 anti-X(a) U/mL and on warfarin with an INR ≥ 2.0 were associated with significant reductions in VTE recurrence, while the hazard with active cancer was significantly increased. Time from VTE onset to heparin start, duration of overlapping heparin and warfarin, and inferior vena cava (IVC) filter placement were not independent predictors of recurrence. At a heparin dose ≥ 30 000 U/d, the median proportion of time with an APTT ≥ 0.2 anti-X(a) U/mL was 92%, suggesting that routine APTT monitoring and heparin dose adjustment may be unnecessary. In summary, lower-intensity heparin and standard-intensity warfarin anticoagulation are effective in preventing VTE recurrence.

Citing Articles

Thromboembolism in Patients with Cancer: A Practical Guide to Recurrent Events.

Kozhukhov S, Dovganych N Rev Cardiovasc Med. 2024; 25(11):406.

PMID: 39618864 PMC: 11607493. DOI: 10.31083/j.rcm2511406.

Incidence, risk factors and the prognostic role of thromboembolic events (TEEs) amongst patients with metastatic pancreatic adenocarcinoma (PAAD): a retrospective, single-center analysis.

Santos C, de Assis Maia Jr F, Camandaroba M, de Jesus V Ecancermedicalscience. 2024; 18:1738.

PMID: 39421185 PMC: 11484686. DOI: 10.3332/ecancer.2024.1738.

Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?.

Cross B, Turner R, Zhang J, Pirmohamed M Pharmacogenomics J. 2024; 24(2):7.

PMID: 38443337 PMC: 10914631. DOI: 10.1038/s41397-024-00329-y.

Incidence and factors associated with deep vein thrombosis among hospitalized adult patients at Hawassa university comprehensive specialized hospital Hawassa city, Sidama, Ethiopia: retrospective cohort study.

Alemu T, Adule A, Sorato M, Borsamo A J Thromb Thrombolysis. 2023; 57(1):164-174.

PMID: 37704907 DOI: 10.1007/s11239-023-02889-5.

Epidemiology and prevention of venous thromboembolism.

Lutsey P, Zakai N Nat Rev Cardiol. 2022; 20(4):248-262.

PMID: 36258120 PMC: 9579604. DOI: 10.1038/s41569-022-00787-6.

References

Wessler S, Morris L . Studies in intravascular coagulation. IV. The effect of heparin and dicumarol on serum-induced venous thrombosis. Circulation. 1955; 12(4):553-6. DOI: 10.1161/01.cir.12.4.553. View

Gallus A, Jackaman J, Tillett J, Mills W, Wycherley A . Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986; 2(8519):1293-6. DOI: 10.1016/s0140-6736(86)91431-5. View

Hirsh J, Bauer K, Donati M, Gould M, Samama M, Weitz J . Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):141S-159S. DOI: 10.1378/chest.08-0689. View

Warkentin T, Greinacher A, Koster A, Lincoff A . Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):340S-380S. DOI: 10.1378/chest.08-0677. View

Lijfering W, Veeger N, Middeldorp S, Hamulyak K, Prins M, Buller H . A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood. 2009; 114(10):2031-6. DOI: 10.1182/blood-2009-04-215418. View

Hull R, Hirsh J, Jay R, Carter C, England C, Gent M . Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982; 307(27):1676-81. DOI: 10.1056/NEJM198212303072704. View

Anand S, Bates S, Ginsberg J, Levine M, Buller H, Prins M . Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med. 1999; 159(17):2029-32. DOI: 10.1001/archinte.159.17.2029. View

Rosendaal F, Cannegieter S, van der Meer F, Briet E . A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69(3):236-9. View

Douketis J, Foster G, Crowther M, Prins M, Ginsberg J . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med. 2000; 160(22):3431-6. DOI: 10.1001/archinte.160.22.3431. View

10.

Chiu H, Hirsh J, Yung W, REGOECZI E, Gent M . Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood. 1977; 49(2):171-84. View

11.

Basu D, Gallus A, Hirsh J, Cade J . A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972; 287(7):324-7. DOI: 10.1056/NEJM197208172870703. View

12.

Anand S, Ginsberg J, Kearon C, Gent M, Hirsh J . The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med. 1996; 156(15):1677-81. View

13.

Raschke R, Reilly B, Guidry J, Fontana J, Srinivas S . The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med. 1993; 119(9):874-81. DOI: 10.7326/0003-4819-119-9-199311010-00002. View

14.

Olson J, Arkin C, Brandt J, Cunningham M, Giles A, KOEPKE J . College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998; 122(9):782-98. View

15.

Kearon C, Gent M, Hirsh J, Weitz J, Kovacs M, Anderson D . A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999; 340(12):901-7. DOI: 10.1056/NEJM199903253401201. View

16.

Wessler S, Gitel S . Warfarin. From bedside to bench. N Engl J Med. 1984; 311(10):645-52. DOI: 10.1056/NEJM198409063111007. View

17.

Heit J, Leibson C, Ashrani A, Petterson T, Bailey K, Melton 3rd L . Is diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based case-control study. Arterioscler Thromb Vasc Biol. 2009; 29(9):1399-405. PMC: 2735343. DOI: 10.1161/ATVBAHA.109.189290. View

18.

Barritt D, Jordan S . Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet. 1960; 1(7138):1309-12. DOI: 10.1016/s0140-6736(60)92299-6. View

19.

Hull R, Raskob G, Hirsh J, Jay R, Leclerc J, Geerts W . Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986; 315(18):1109-14. DOI: 10.1056/NEJM198610303151801. View

20.

Baglin T, Barrowcliffe T, Cohen A, Greaves M . Guidelines on the use and monitoring of heparin. Br J Haematol. 2006; 133(1):19-34. DOI: 10.1111/j.1365-2141.2005.05953.x. View